Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
Purpose. To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. Methods. We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled tri...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/2324400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434790779944960 |
|---|---|
| author | Ji Wen Huifang Hu Menglin Chen Hang Yang Yi Zhao Yi Liu |
| author_facet | Ji Wen Huifang Hu Menglin Chen Hang Yang Yi Zhao Yi Liu |
| author_sort | Ji Wen |
| collection | DOAJ |
| description | Purpose. To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. Methods. We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled trials, cohort studies, case controls, and case reports. Results. Seven studies, including 11 patients, were included in the final systematic analysis. Of the 11 patients, there were 5 cases of juvenile idiopathic arthritis- (JIA-) associated uveitis, 1 case of rheumatoid arthritis- (RA-) associated keratitis, 1 case of RA-associated scleritis, 1 case of psoriasis-associated conjunctivitis, 2 cases of noninfectious scleritis, and 1 case of uveitis with suspected autoimmune disease. None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy. Irrespective of whether they were suffering from uveitis, scleritis, or other types of ocular inflammation, all 11 patients showed an improvement to JAK inhibitors without significant side effects. Different types of JAK inhibitors might be associated with different responses when used to treat ocular inflammation. Conclusions. JAK inhibitors may represent an alternative treatment option for patients with autoimmune ocular inflammation. |
| format | Article |
| id | doaj-art-e3b02818f8a44781b8b7bdb39ffccf05 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-e3b02818f8a44781b8b7bdb39ffccf052025-08-20T03:26:31ZengWileyJournal of Immunology Research2314-71562021-01-01202110.1155/2021/2324400Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic ReviewJi Wen0Huifang Hu1Menglin Chen2Hang Yang3Yi Zhao4Yi Liu5Department of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyDepartment of Occupational Health and Toxicity/NephrologyDepartment of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyPurpose. To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. Methods. We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled trials, cohort studies, case controls, and case reports. Results. Seven studies, including 11 patients, were included in the final systematic analysis. Of the 11 patients, there were 5 cases of juvenile idiopathic arthritis- (JIA-) associated uveitis, 1 case of rheumatoid arthritis- (RA-) associated keratitis, 1 case of RA-associated scleritis, 1 case of psoriasis-associated conjunctivitis, 2 cases of noninfectious scleritis, and 1 case of uveitis with suspected autoimmune disease. None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy. Irrespective of whether they were suffering from uveitis, scleritis, or other types of ocular inflammation, all 11 patients showed an improvement to JAK inhibitors without significant side effects. Different types of JAK inhibitors might be associated with different responses when used to treat ocular inflammation. Conclusions. JAK inhibitors may represent an alternative treatment option for patients with autoimmune ocular inflammation.http://dx.doi.org/10.1155/2021/2324400 |
| spellingShingle | Ji Wen Huifang Hu Menglin Chen Hang Yang Yi Zhao Yi Liu Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review Journal of Immunology Research |
| title | Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review |
| title_full | Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review |
| title_fullStr | Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review |
| title_full_unstemmed | Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review |
| title_short | Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review |
| title_sort | role of janus kinase jak inhibitor in autoimmune ocular inflammation a systematic review |
| url | http://dx.doi.org/10.1155/2021/2324400 |
| work_keys_str_mv | AT jiwen roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview AT huifanghu roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview AT menglinchen roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview AT hangyang roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview AT yizhao roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview AT yiliu roleofjanuskinasejakinhibitorinautoimmuneocularinflammationasystematicreview |